1
|
Castorino K, Polsky S, O'Malley G, Levister C, Nelson K, Farfan C, Brackett S, Puhr S, Levy CJ. Performance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes. Diabetes Technol Ther 2020; 22:943-947. [PMID: 32324061 PMCID: PMC7757524 DOI: 10.1089/dia.2020.0085] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Background: The aim of this study was to determine the performance of the Dexcom G6 continuous glucose monitoring (CGM) system across three sensor wear sites in pregnant women with diabetes in the second or third trimesters. Methods: Participants with type 1 (T1D), type 2 (T2D), or gestational (GDM) diabetes mellitus were enrolled at three sites. Each wore two G6 sensors on the abdomen, upper buttock, and/or posterior upper arm for 10 days and underwent a 6-h clinic session between days 3 and 7 of sensor wear, during which YSI reference blood glucose values were obtained every 30 min. No intentional glucose manipulations were performed. Accuracy metrics included the proportion of CGM values that were within ±20% of paired reference values >100 mg/dL or ±20 mg/dL of YSI values ≤100 mg/dL (hereafter referred to as %20/20), as well as the analogous %15/15, %30/30, and %40/40. The mean absolute relative difference (MARD) between CGM-YSI pairs was also calculated. Results: Thirty-two participants with T1D (n = 20), T2D (n = 3), or GDM (n = 9) were enrolled: 19 were in the second trimester and 13 were in the third trimester of pregnancy. Compared with the reference, 92.5% of CGM values were within ±20%/20 mg/dL. The overall MARD and that of sensors worn on the abdomen, upper buttock, and posterior upper arm was 10.3%, 11.5%, 11.2%, and 8.7%, respectively. There were no device-related adverse events. Skin reactions at the insertion sites were absent or minor. Conclusions: The Dexcom G6 CGM system is accurate and safe in pregnant women with diabetes.
Collapse
Affiliation(s)
- Kristin Castorino
- Sansum Diabetes Research Institute, Santa Barbara, California, USA
- Address correspondence to: Kristin Castorino, DO, Sansum Diabetes Research Institute, 2219 Bath Street, Santa Barbara, CA 93105, USA
| | - Sarit Polsky
- Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Grenye O'Malley
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Camilla Levister
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Kristen Nelson
- Sansum Diabetes Research Institute, Santa Barbara, California, USA
| | - Christian Farfan
- Sansum Diabetes Research Institute, Santa Barbara, California, USA
| | - Scott Brackett
- Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA
| | - Sarah Puhr
- Dexcom, Inc., San Diego, California, USA
| | - Carol J. Levy
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| |
Collapse
|
2
|
Inoue N, Farfan C, Gonzales GF. Effect of butanolic fraction of yellow and black maca (Lepidium meyenii
) on the sperm count of adult mice. Andrologia 2016; 48:915-21. [DOI: 10.1111/and.12679] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/19/2015] [Indexed: 01/22/2023] Open
Affiliation(s)
- N. Inoue
- Department of Biological and Physiological Sciences; Faculty of Sciences and Philosophy; Universidad Peruana Cayetano Heredia; Lima Peru
- Research Circle on Plants with effects on Health; Universidad Peruana Cayetano Heredia; Lima Peru
| | - C. Farfan
- Department of Biological and Physiological Sciences; Faculty of Sciences and Philosophy; Universidad Peruana Cayetano Heredia; Lima Peru
- Research Circle on Plants with effects on Health; Universidad Peruana Cayetano Heredia; Lima Peru
| | - G. F. Gonzales
- Department of Biological and Physiological Sciences; Faculty of Sciences and Philosophy; Universidad Peruana Cayetano Heredia; Lima Peru
- Research Circle on Plants with effects on Health; Universidad Peruana Cayetano Heredia; Lima Peru
- Instituto de Investigaciones de la Altura; Universidad Peruana Cayetano Heredia; Lima Peru
| |
Collapse
|
3
|
Sanchez JS, Farfan C, Villacampa F, Velasco G, Benitez J, Rodriguez C, Calderon M, Cañamares I, Cortes-Funes H, Castellano D. Genetic Polymorphisms and Sunitinib Toxicity in Metastatic Renal-Cell Carcinoma. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33422-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Ciruelos EM, Castaneda CA, Andrés E, Gomez HL, Castellano D, Mendiola C, Manso L, Ghanem I, Farfan C, Cortes-Funes H. P3-05-06: Progression of Breast Cancer Molecular Subtypes through Different Clinical Stages. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-05-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose : Molecular classification of breast cancer (BC) through immunohistochemistry classifies patients globally in 4 subtypes with similar features and prognosis. The present study was designed to compare features of BC subtypes in early versus locally advanced clinical stages. A secondary objective was compare molecular subtypes of the primary vs recurrences.
Methods : The study included 1621 patients with non-metastatic invasive BC that were consecutively diagnosed at Hospital Universitario 12 de Octubre, Madrid, between 1997 and 2007. Luminal A was defined as ER+ and PR+, HER2−negative and Ki67 < 14%. Luminal B was defined as PR-negative, HER2−positive or ki67≥14%. HER2 was defined as ER and PR-negative, and HER2−positive.Triple negative (TN) were tumors with ER, PR and HER2 -negativity. Clinicopathological characteristics and outcomes were retrospectively reviewed. Variables were compared with the X2 test, and survival curves were evaluated with Kaplan-Meier method.
Results : Most patients were diagnosed as T1 (48%) and T2 (39.7%) clinical stages, and classified as Luminal B (49%) and Luminal A (29%). GIII frequency increased from T1 to T3-4 in Luminal A (p=0.002), and Luminal B (p=0.051) subtypes, but not in HER2 (p=0.867) or TN (p=0.53).
Molecular subtypes carry significant different prognosis (DFS and OS) in all T stages except for T1a cases. When T3-4 and T1 stages of the same molecular subtype were compared, a significant shorter DFS were found for more advanced stages in the Luminal A (p=0.0002), Luminal B (0.0001) and TN (0.0017), but not for HER2 (p=0.54) subtype. And, similar results were found for OS.
We compared molecular subtypes in the primary tumor and in the metastatic site in 83 cases (excluding contralateral recurrences) and found change of phenotype in 54% of the cases. Changes from Luminal A to a more aggressive phenotype were more frequent than in the opposite situation (14 vs 2 cases).
Conclusion : Despite the molecular classification of early-stage BC that classifies patients in well-defined prognostic subgroups, tumors are continuously changing and tumor behavior becomes more aggressive through progression. Therefore, even tumors with favorable phenotype could loss their good prognosis in locally advanced stages. Obtention of tumor tissue at metastatic sites is also mandatory to a better selection of systemic therapies in relapsed patients.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-05-06.
Collapse
Affiliation(s)
- EM Ciruelos
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - CA Castaneda
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - E Andrés
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - HL Gomez
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - D Castellano
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - C Mendiola
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - L Manso
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - I Ghanem
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - C Farfan
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| | - H Cortes-Funes
- 1Hospital Universitario 12 de Octubre, Madrid, Spain; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru
| |
Collapse
|
6
|
Mishler JM, Janes AW, Lowes B, Farfan C, Emerson PM. Utilization of a new strength citrate anticoagulant during centrifugal plateletpheresis. I. Assessment of donor effects. Br J Haematol 1976; 34:387-94. [PMID: 990180 DOI: 10.1111/j.1365-2141.1976.tb03585.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
A reduction of donor effects during centrifugal plateletpheresis with the Haemonetics Blood Processor was achieved by reducing the concentration of the citrate anticoagulant. Serum citrate and ionized calcium levels, immediately and 1 h post-pheresis, were affected to a lesser extent by using 5.0 g total ionized citrate (TIC) THAN WITH EITHER 8.0 G OR 11.0 G. Total calcium, bicarbonate, prothrombin time, partial thromboplastin time, ECG, and platelet counts were affected to a similar degree by all three TIC formulations. The total number of platelets collected per litre of blood processed was not significantly different among the three TIC formulations. In vitro studies employing the screen filtration pressure (SFP) technique showed no evidence of platelet aggregates in whole blood collected into either 0.01 M or 0.005 M citrate and agitated or left stationary at room temperature for 5 h. The use of different citrate concentrations in plateletpheresis is discussed.
Collapse
|